China Universal Asset Management Company’s Centessa Pharmaceuticals CNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-21,225
Closed -$843K – 521
2026
Q1
$843K Buy
21,225
+5,504
+35% +$141K 0.06% 212
2025
Q4
$393K Sell
15,721
-1,095
-7% -$27.7K 0.03% 281
2025
Q3
$408K Sell
16,816
-2,365
-12% -$42K 0.03% 266
2025
Q2
$252K Buy
19,181
+870
+5% +$11K 0.02% 291
2025
Q1
$263K Sell
18,311
-598
-3% -$9.79K 0.02% 291
2024
Q4
$317K Buy
18,909
+5,316
+39% +$88.1K 0.03% 293
2024
Q3
$217K Buy
13,593
+6,785
+100% +$83.1K 0.02% 294
2024
Q2
$61.5K Sell
6,808
-4,009
-37% -$38K 0.01% 344
2024
Q1
$122K Buy
10,817
+4,423
+69% +$41.9K 0.02% 350
2023
Q4
$50.9K Buy
6,394
+5,037
+371% +$33.8K 0.01% 369
2023
Q3
$8.78K Buy
1,357
+666
+96% +$4.56K ﹤0.01% 355
2023
Q2
$4.28K Sell
691
-21
-3% -$100 ﹤0.01% 384
2023
Q1
$2.74K Buy
712
+179
+34% +$655 ﹤0.01% 422
2022
Q4
$1.65K Buy
533
+52
+11% +$193 ﹤0.01% 383
2022
Q3
$2K Buy
+481
New +$2.2K ﹤0.01% 346

China Universal Asset Management Company's CNTA Position: Q2 2026 in Review

China Universal Asset Management Company sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 21,225 shares — an estimated $843K sold.

China Universal Asset Management Company first reported a position in CNTA in Q3 2022 and held it in 15 quarters. The position peaked at $843K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • China Universal Asset Management Company reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • China Universal Asset Management Company sold 21,225 Centessa Pharmaceuticals shares in Q2 2026, an estimated $843K.
  • China Universal Asset Management Company first reported a position in Centessa Pharmaceuticals in Q3 2022 and held it in 15 quarters.
  • China Universal Asset Management Company's Centessa Pharmaceuticals position peaked at $843K in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.